HC Wainwright & Co. Maintains Buy on BriaCell Therapeutics, Lowers Price Target to $15
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has maintained a Buy rating on BriaCell Therapeutics but lowered the price target from $18 to $15.
September 19, 2024 | 10:32 am
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
HC Wainwright & Co. has maintained a Buy rating on BriaCell Therapeutics but lowered the price target from $18 to $15, indicating a slightly less optimistic outlook.
The maintenance of a Buy rating suggests continued confidence in BriaCell's potential, but the lowered price target indicates a tempered outlook, which could lead to neutral short-term price movement.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100